Acasti Pharma found using ticker (ACST) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 3.15 and 1.89 calculating the mean target price we have 2.52. With the stocks previous close at 0.33 this is indicating there is a potential upside of 663.6%. There is a 50 day moving average of 0.28 and the 200 day moving average is 0.4. The company has a market capitalisation of $39m. You can visit the company’s website by visiting: http://www.acastipharma.com
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.